CIK 0001326732 · Accelerated filer
Xencor Inc
Sign in to watch- Ticker
- XNCR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 201622502
- Phone
- 626-305-5900
- Business address
- 465 N. HALSTEAD ST., SUITE 200, PASADENA, CA, 91107
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,591,617
- in 2 filings
Net −$3,591,617. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Eckert Celia SVP, GENERAL COUNSEL | Sale | −1,492 | $11.90 | $18K | 81,929 |
| 2026-03-03 | Desjarlais John R SR. VICE PRESIDENT & CSO | Sale | −2,663 | $11.90 | $32K | 270,451 |
| 2026-03-03 | Dahiyat Bassil I PRESIDENT & CEO | Sale | −6,758 | $11.90 | $80K | 567,792 |
| 2026-03-02 | Cornelissen Bart Jan SR. VICE PRESIDENT & CFO | Grant or award | +19,458 | 81,914 | ||
| 2026-03-02 | Cornelissen Bart Jan SR. VICE PRESIDENT & CFO | Grant or award · Stock Option (Right to Buy) | +116,750 | 116,750 | ||
| 2026-03-02 | Eckert Celia SVP, GENERAL COUNSEL | Grant or award | +18,680 | 83,421 | ||
| 2026-03-02 | Eckert Celia SVP, GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +112,080 | 112,080 | ||
| 2026-03-02 | Desjarlais John R SR. VICE PRESIDENT & CSO | Grant or award | +24,907 | 273,114 | ||
| 2026-03-02 | Desjarlais John R SR. VICE PRESIDENT & CSO | Grant or award · Stock Option (Right to Buy) | +149,440 | 149,440 | ||
| 2026-03-02 | Dahiyat Bassil I PRESIDENT & CEO | Grant or award | +97,291 | 574,550 | ||
| 2026-03-02 | Dahiyat Bassil I PRESIDENT & CEO | Grant or award · Stock Option (Right to Buy) | +583,748 | 583,748 | ||
| 2026-01-23 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise | +5,322 | $12.51 | $67K | 248,207 |
| 2026-01-23 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise · Stock Option (Right to Buy) | −5,322 | 0 | ||
| 2025-12-22 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise | +6,311 | $12.51 | $79K | 242,885 |
| 2025-12-22 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise · Stock Option (Right to Buy) | −6,311 | 5,322 | ||
| 2025-12-22 | Dahiyat Bassil I PRESIDENT & CEO | Option exercise | +10,624 | $12.51 | $133K | 477,259 |
| 2025-12-22 | Dahiyat Bassil I PRESIDENT & CEO | Option exercise · Stock Option (Right to Buy) | −10,624 | 0 | ||
| 2025-12-19 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise | +73,367 | $12.51 | $918K | 309,941 |
| 2025-12-19 | Desjarlais John R SR. VICE PRESIDENT & CSO | Sale | −73,367 | $15.72 | $1.2M | 236,574 |
| 2025-12-19 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise · Stock Option (Right to Buy) | −73,367 | 11,633 |
Page 3 of 11 · 211 trades